Advertisement

Journal of Inherited Metabolic Disease

, Volume 39, Issue 4, pp 573–584 | Cite as

Improving long term outcomes in urea cycle disorders-report from the Urea Cycle Disorders Consortium

  • Susan E. Waisbren
  • Andrea L. Gropman
  • Members of the Urea Cycle Disorders Consortium (UCDC)
  • Mark L. Batshaw
SSIEM 2015

Abstract

The Urea Cycle Disorders Consortium (UCDC) has conducted, beginning in 2006, a longitudinal study (LS) of eight enzyme deficiencies/transporter defects associated with the urea cycle. These include N-acetylglutamate synthase deficiency (NAGSD); Carbamyl phosphate synthetase 1 deficiency (CPS1D); Ornithine transcarbamylase deficiency (OTCD); Argininosuccinate synthetase deficiency (ASSD) (Citrullinemia); Argininosuccinate lyase deficiency (ASLD) (Argininosuccinic aciduria); Arginase deficiency (ARGD, Argininemia); Hyperornithinemia, hyperammonemia, homocitrullinuria (HHH) syndrome (or mitochondrial ornithine transporter 1 deficiency [ORNT1D]); and Citrullinemia type II (mitochondrial aspartate/glutamate carrier deficiency [CITRIN]). There were 678 UCD patients enrolled in 14 sites in the U.S., Canada, and Europe at the writing of this paper. This review summarizes findings of the consortium related to outcome, focusing primarily on neuroimaging findings and neurocognitive function. Neuroimaging studies in late onset OTCD offered evidence that brain injury caused by biochemical dysregulation may impact functional neuroanatomy serving working memory processes, an important component of executive function and regulation. Additionally, there were alteration in white mater microstructure and functional connectivity at rest. Intellectual deficits in OTCD and other urea cycle disorders (UCD) vary. However, when neuropsychological deficits occur, they tend to be more prominent in motor/performance areas on both intelligence tests and other measures. In some disorders, adults performed significantly less well than younger patients. Further longitudinal follow-up will reveal whether this is due to declines throughout life or to improvements in diagnostics (especially newborn screening) and treatments in the younger generation of patients.

Keywords

Autism Spectrum Disorder Newborn Screening Argininosuccinate Urea Cycle Disorder Argininosuccinate Lyase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

The Urea Cycle Disorders Consortium (UCDC; U54HD061221) is a part of the National Institutes of Health (NIH) Rare Disease Clinical Research Network (RDCRN), supported through collaboration between the Office of Rare Diseases Research (ORDR), the National Center for Advancing Translational Science (NCATS and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The UCDC is also supported by the O’Malley Foundation, the Rotenberg Family Fund, the Dietmar-Hopp Foundation, and the Kettering Fund. The Neuropsychology Network is acknowledged for help with data collection and analyses. 

Compliance with ethical standards

Conflict of interest

Mark Batshaw declares that he has no conflict of interest.

Andrea Gropman declares that she has a grant through the Urea Cycle Disorders Consortium funded by NIH.

Susan Waisbren declares that she has a subcontract from the Children’s National Health System through the Urea Cycle Disorders Consortium funded by the NIH.

Informed consent

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 (5). Informed consent was obtained from all patients for being included in the study.

Animal rights

This article does not contain any studies with animal subjects performed by the any of the authors.

References

  1. Albrecht J, Zielińska M, Norenberg MD (2010) Glutamine as a mediator of ammonia neurotoxicity: a critical appraisal. Biochem Pharmacol 80:1303–1308CrossRefPubMedPubMedCentralGoogle Scholar
  2. Batshaw ML, Brusilow SW, Waber L et al (1982) Treatment of inborn errors of urea synthesis: activation of alternate pathways of waste nitrogen synthesis and excretion. N Engl J Med 306:1387–1392CrossRefPubMedGoogle Scholar
  3. Batshaw ML, Msall M, Beaudet AL, Trojak J (1986) Risk of serious illness in heterozygotes for ornithine transcarbamylase deficiency. J Pediatr 108(2):236–241CrossRefPubMedGoogle Scholar
  4. Batshaw ML, MacArthur RB, Tuchman M (2001) Alternative pathway therapy for urea cycle disorders: twenty years later. J Pediatr 138:S46–S55CrossRefPubMedGoogle Scholar
  5. Batshaw ML, Tuchman M, Summar M, Seminara J, Members of the Urea Cycle Disorders Consortium (2014) A longitudinal study of urea cycle disorders. Mol Genet Metab 113(1-2):127–130CrossRefPubMedPubMedCentralGoogle Scholar
  6. Brusilow SW, Batshaw ML, Valle D (1979) New pathways of waste nitrogen excretion in inborn errors of urea synthesis. Lancet 2:452–454CrossRefPubMedGoogle Scholar
  7. Campeau PM, Pivalizza PJ, Miller G, McBride K, Karpen S, Goss J, Lee BH (2010) Early orthotopic liver transplantation in urea cycle defects: follow up of a developmental outcome study. Mol Genet Metab 100(Suppl 1):S84–S87CrossRefPubMedPubMedCentralGoogle Scholar
  8. Gropman AL, Fricke ST, Seltzer RR et al (2008) 1H MRS identifies symptomatic and asymptomatic subjects with partial ornithine transcarbamylase deficiency. Mol Genet Metab 95:21–30CrossRefPubMedPubMedCentralGoogle Scholar
  9. Gropman AL, Gertz B, Shattuck K, Kahn IL, Seltzer R, Krivitsky L, Van Meter J (2010) Diffusion tensor imaging detects areas of abnormal white matter microstructure in patients with partial ornithine transcarbamylase deficiency. AJNR 31:1719–1723CrossRefPubMedPubMedCentralGoogle Scholar
  10. Gropman AL, Shattuck K, Prust MJ et al (2013) Altered neural activation in ornithine transcarbamylase deficiency during executive cognition: an fMRI study. Hum Brain Mapp 34:753–761CrossRefPubMedGoogle Scholar
  11. Gyato K, Wray J, Huang ZJ, Yudkoff M, Batshaw ML (2004) Metabolic and neuropsychological phenotype in women heterozygous for ornithine transcarbamylase deficiency. Ann Neurol 55:80–86CrossRefPubMedGoogle Scholar
  12. Krivitzky L, Babikian T, Lee HS, Thomas NH, Burk-Paull KL, Batshaw ML (2009) Intellectual, adaptive, and behavioral functioning in children with urea cycle disorders. Pediatr Res 66(1):96–101Google Scholar
  13. Msall M, Batshaw ML, Suss R, Brusilow SW, Mellits ED (1984) Neurologic outcome in children with inborn errors of urea synthesis. N Engl J Med 310:1500–1505CrossRefPubMedGoogle Scholar
  14. Msall M, Monahan PS, Chapanis N, Batshaw ML (1988) Cognitive development in children with inborn errors of urea synthesis. Acta Paediatr Jpn 30:435–441CrossRefPubMedGoogle Scholar
  15. Pacheco-Colón I, Washington SD, Sprouse C, Helman G, Gropman AL, VanMeter JW (2015) Reduced functional connectivity of default mode and set-maintenance networks in ornithine transcarbamylase deficiency. PLoS One 10(6):e0129595Google Scholar
  16. Perito ER, Rhee S, Roberts JP, Rosenthal P (2014) Pediatric liver transplantation for urea cycle disorders and organic acidemias: united network for organ sharing data for 2002–2012. Liver Transpl 20(1):89–99CrossRefPubMedGoogle Scholar
  17. Seminara J, Tuchman M, Krivitzky L et al (2010) Establishing a consortium for the study of rare diseases: the urea cycle disorders consortium. Mol Genet Metab 100(Suppl 1):S97–S105CrossRefPubMedPubMedCentralGoogle Scholar
  18. Sprouse C, King J, Helman G et al (2014) Investigating neurological deficits in carriers and affected patients with ornithine transcarbamylase deficiency. Mol Genet Metab 113(1-2):136–141CrossRefPubMedPubMedCentralGoogle Scholar
  19. Summar ML, Koelker S, Freedenberg D, Le Mons C, Haberle J, Lee HS, Kirmse B (2013) European Registry and Network for Intoxication Type Metabolic Diseases (E-IMD). Electronic address: http://www.e-imd.org/en/index.phtml; Members of the Urea Cycle Disorders Consortium (UCDC). Electronic address: http://rarediseasesnetwork.epi.usf.edu/ucdc/. The incidence of urea cycle disorders. Mol Genet Metab 110(1–2):179–180. doi: 10.1016/j.ymgme.2013.07.008

Copyright information

© SSIEM 2016

Authors and Affiliations

  • Susan E. Waisbren
    • 1
  • Andrea L. Gropman
    • 2
  • Members of the Urea Cycle Disorders Consortium (UCDC)
  • Mark L. Batshaw
    • 3
  1. 1.Boston Children’s HospitalHarvard Medical SchoolBostonUSA
  2. 2.Children’s Research Institute, Children’s National Health SystemWashingtonUSA
  3. 3.Departments of Pediatrics and NeurologyGeorge Washington University School of Medicine and Health SciencesWashingtonUSA

Personalised recommendations